RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31
ROCKET PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.24+0.06 (+2.75%)
Close on Oct 19, 2026
- Market cap
- $256.51M
- P/E (TTM)
- –
- Dividend yield
- –
Rocket Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Rocket Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $245.90M | $166.30M |
| Enterprise Value | -$37.80M | $88.19M |
| PB Ratio | 0.67 | 2.03 |
| P/TBV Ratio | 0.81 | 2.29 |
Income (trailing twelve months)
| Measure | Rocket Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $0 | $58.34M |
| Operating Income | -$191.64M | -$21.40M |
| Net Income | -$17.25M | -$22.46M |
| EBITDA | -$184.04M | -$16.91M |
| EPS (Diluted) | -$0.17 | -$0.83 |
Returns
| Measure | Rocket Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -4.77% | -53.2% |
| Return on Assets (ROA) | -4.09% | -40.9% |
| Return on Invested Capital (ROIC) | -180.4% | -32.4% |
| Return on Capital Employed (ROCE) | -48.9% | -38.1% |
Balance sheet
| Measure | Rocket Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $283.70M | $61.43M |
| Net Cash (Debt) | $283.70M | $15.35M |
| Net Cash Per Share | $2.58 | $0.66 |
| Equity (Book Value) | $368.83M | $49.09M |
| Book Value Per Share | $3.36 | $1.37 |
| Tangible Book Value | $304.53M | $23.52M |
| Working Capital | $258.23M | $76.81M |
Financial position
| Measure | Rocket Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 9.24 | 3.34 |
| Quick Ratio | 9.06 | 2.44 |
| Interest Coverage | -101.29 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Rocket Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$170.27M | -$12.35M |
| Capital Expenditures | -$127.00K | -$1.08M |
| Free Cash Flow | -$170.39M | -$20.22M |
| FCF Per Share | -$1.55 | -$0.42 |
Efficiency
| Measure | Rocket Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.39 |
| Revenue Per Employee | $0 | $404.87K |
| Profits Per Employee | -$85.40K | -$703.34K |
| Employee Count | 202 | 74 |
Dividends and yields
| Measure | Rocket Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -7.02% | -23.3% |
| FCF Yield | -69.3% | -8.72% |
Shares
| Measure | Rocket Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 109,775,000 | 58,127,000 |
| Shares Change (YoY) | 9.01% | 10.9% |
| Shares Change (QoQ) | 0.38% | 0.54% |
| Float | 85,156,700 | 49,136,700 |
| Shares Held by Insiders | 22.4% | 11.6% |
| Shares Held by Institutions | 90.9% | 59.4% |
Scores
| Measure | Rocket Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -2.56 | -0.22 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Rocket Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.